Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company?s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates, including Binimetinib, an MEK inhibitor for cancer; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company?s partnered clinical program
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-0.71||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||9.82%||Sales Growth - Q/Q||-75.48%||P/E||-10.59|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-2.94%||ROE||-12.23%||ROI||-3.87%|
|Current Ratio||4.38||Quick Ratio||Long Term Debt/Equity||0.71||Debt Ratio||0.9|
|Gross Margin||-7.14%||Operating Margin||-5.45%||Net Profit Margin||-13.45%||Dividend Payout Ratio|
|Cash From Financing Activities||38.85 M||Cash From Investing Activities||12.56 M||Cash From Operating Activities||21.47 M||Gross Profit||-5.54 M|
|Net Profit||58.31 M||Operating Profit||54.47 M||Total Assets||208.44 M||Total Current Assets||196.59 M|
|Total Current Liabilities||44.92 M||Total Debt||107.98 M||Total Liabilities||158.29 M||Total Revenue||6.6 M|
|High 52 week||24.85||Low 52 week||12.92||Last close||22.39||Last change||0.18%|
|RSI||26.37||Average true range||0.73||Beta||1.32||Volume||2.74 M|
|Simple moving average 20 days||-5.82%||Simple moving average 50 days||-3.78%||Simple moving average 200 days||27.59%|
|Performance Week||-6.2%||Performance Month||-8.43%||Performance Quart||28.31%||Performance Half||45.39%|
|Performance Year||46.44%||Performance Year-to-date||57.12%||Volatility daily||2.34%||Volatility weekly||5.23%|
|Volatility monthly||10.71%||Volatility yearly||37.11%||Relative Volume||178.42%||Average Volume||3.3 M|
|New High||0.46%||New Low|
2019-06-13 08:01:40 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-06-11 08:02:07 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-06-10 09:39:39 | Here is What Hedge Funds Think About Array Biopharma Inc ARRY
2019-06-10 08:02:39 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-06-08 08:09:37 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-06-06 09:31:01 | Why Is Array BioPharma ARRY Up 27.1% Since Last Earnings Report?
2019-06-04 16:05:00 | Array BioPharma to Present at the Goldman Sachs 40?? Annual Global Healthcare Conference
2019-06-04 09:21:00 | 3 Cancer Stocks Given a Lift by Amgen
2019-06-04 08:04:30 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-06-03 12:18:00 | Here's Why Mirati Therapeutics Is Jumping Today
2019-05-30 10:34:00 | 2 Ultra-High-Growth Biotech Stocks to Buy Now
2019-05-29 16:05:00 | Array BioPharma to Present at the Jefferies 2019 Global Healthcare Conference
2019-05-29 11:55:00 | Array BioPharma Announces Presentation of Updated Overall Survival from the Phase 3 COLUMBUS Trial of BRAFTOVI + MEKTOVI in advanced BRAF-mutant Melanoma at 2019 ASCO Annual Meeting
2019-05-23 08:54:12 | Array BioPharma Inc. ARRY Shares March Higher, Can It Continue?
2019-05-22 17:13:09 | Array BioPharma Gains on Colorectal Cancer Study Success
2019-05-22 08:39:48 | 3 Big Stock Charts for Wednesday: Oracle, Lamb Weston Holdings and TJX Companies
2019-05-21 16:30:00 | Why Dycom Industries, Array BioPharma, and Circor International Jumped Today
2019-05-21 13:55:27 | Array Biopharma Tests Highs on Clinical Trial Results
2019-05-21 12:42:00 | Here's Why Array BioPharma Is Surging Today
2019-05-21 08:00:01 | Array BioPharma's colorectal cancer combo treatment meets main goals
2019-05-21 08:00:00 | Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAFV600E-mutant Metastatic Colorectal Cancer
2019-05-18 15:18:23 | Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More
2019-05-16 14:51:44 | Why Array BioPharma Shares Fell Thursday
2019-05-10 09:00:01 | All You Need to Know About Array BioPharma ARRY Rating Upgrade to Buy
2019-05-08 09:56:01 | Array BioPharma ARRY Q3 Earnings and Sales Beat Estimates
2019-05-07 21:43:08 | Edited Transcript of ARRY earnings conference call or presentation 7-May-19 1:00pm GMT
2019-05-07 16:18:30 | Boulder biotech firm beats expectations despite year-over-year losses on income, revenue
2019-05-07 15:23:50 | Array Biopharma Inc ARRY Q3 2019 Earnings Call Transcript
2019-05-07 09:15:01 | Array BioPharma ARRY Reports Q3 Loss, Tops Revenue Estimates
2019-05-07 08:05:59 | Array BioPharma: Fiscal 3Q Earnings Snapshot
2019-05-07 08:04:07 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-05-07 08:00:00 | Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2019
2019-04-30 08:02:41 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-04-26 15:37:46 | The Array BioPharma NASDAQ:ARRY Share Price Is Up 610% And Shareholders Are Delighted
2019-04-26 11:25:34 | Did Hedge Funds Drop The Ball On Array Biopharma Inc ARRY ?
2019-03-27 16:16:45 | Analysts Raised Target Price for Array Biopharma in March
2019-03-18 08:00:00 | BRAFTOVI® encorafenib in Combination with MEKTOVI® binimetinib and ERBITUX® cetuximab or panitumumab Recommended by the National Comprehensive Cancer Network® NCCN Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer
2019-03-07 12:18:08 | How Financially Strong Is Array BioPharma Inc. NASDAQ:ARRY?
2019-03-06 07:57:00 | Why Array BioPharma Stock Soared 22.9% in February
2019-03-05 16:05:00 | Array BioPharma to Present at the 39th Annual Cowen Health Care Conference
2019-03-05 14:40:34 | 3 Small Caps Posting Big Gains
2019-03-04 08:35:00 | Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences — Renewed Outlook, Key Drivers of Growth
2019-02-26 13:34:22 | 5 Stocks Seeing Insider Selling Right Now
2019-02-14 14:02:07 | Zoetis ZTS Beats on Q4 Earnings & Sales, Shares Up
2019-02-08 08:03:13 | See what the IHS Markit Score report has to say about Array Biopharma Inc.
2019-02-07 06:34:11 | Will Array BioPharma Continue to Surge Higher?